Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

NCT02526524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

571

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Met DR
DRUG: Met IR
DRUG: Placebo

Sponsor

Elcelyx Therapeutics, Inc.